Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858919 | 0.88 | NR4A2 (0.69) | MAPTNR4A2ALDH1A1KDM4ENPC1 | |
| SCHEMBL3660284 | 0.88 | MAPT (0.69) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL1559335 | 0.87 | MAPT (0.68) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL6029910 | 0.85 | MAPT (0.66) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL1559431 | 0.85 | MAPT (0.70) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL590922 | 0.84 | MAPT (0.73) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL30075344 | 0.84 | MAPT (0.73) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL12480809 | 0.83 | MAPT (0.71) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL25229260 | 0.83 | MAPT (0.63) | MAPTTUBB1NR4A2ALDH1A1KDM4E | |
| SCHEMBL31501108 | 0.82 | NR4A2 (0.78) | MAPTTUBB1NR4A2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009019508-A1 | CALCIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-02-12 | — | — | WO | claimed |
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. | 2021-09-30 | — | — | US | disclosed |
| WO-2021127302-A1 | 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-9548460-B2 | Compound for organic optoelectronic device, organic light emitting diode including the same and display including the organic light emitting diode | CHEIL INDUSTRIES, INC. (KR) | 2017-01-17 | — | — | US | disclosed |
| WO-2010035032-A1 | CALCIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009019508-A1 | CALCIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MAPT 4673/4885TUBB1 4234/4885NR4A2 75/4885 |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | MAPT 3228/4885TUBB1 197/4885NR4A2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.